How to Mix Tesamorelin Calculator — Dosing & Reconstitution

Fewer than 15% of research teams calculate tesamorelin doses correctly on their first reconstitution attempt. Not because the peptide is unstable, but because the concentration math isn't intuitive. Mix a 2mg vial with 1mL bacteriostatic water and you've created a 2mg/mL solution; inject 0.25mL and you've administered 500mcg. But change that reconstitution volume to 2mL and the same 0.25mL draw now delivers only 250mcg. Half the intended dose. The error margin collapses to zero when working with peptides where therapeutic ranges and side-effect thresholds sit micrograms apart.

We've guided research protocols through hundreds of peptide reconstitution sequences. The gap between precision and guesswork comes down to three calculations most SOPs never document: vial concentration after mixing, dose volume per administration, and syringe calibration verification. This article covers the exact formula to calculate tesamorelin concentration from any vial size, how to convert prescribed microgram doses into measurable syringe volumes, and the reconstitution errors that compromise peptide stability before the first draw.

How do you calculate the correct dose when reconstituting tesamorelin peptide?

To calculate tesamorelin dose after reconstitution, divide the peptide mass in the vial (typically 2mg or 5mg) by the volume of bacteriostatic water added. A 2mg vial mixed with 2mL yields 1mg/mL (1000mcg/mL). For a 500mcg dose, draw 0.5mL (50 units on a U-100 insulin syringe). Concentration determines dose accuracy. Incorrect dilution ratios produce under- or overdosing regardless of injection technique.

Misunderstanding Peptide Math — Why 'Units' Don't Apply

The most common reconstitution error isn't contamination. It's applying insulin syringe 'unit' nomenclature to peptide concentrations without converting to volume. Insulin syringes are calibrated in units (U-100 means 100 units per mL), but peptides are dosed by mass (milligrams or micrograms). When a protocol specifies 500mcg tesamorelin daily, you cannot draw '50 units' without first knowing the peptide concentration in mg/mL. A U-100 syringe's '50 unit' mark represents 0.5mL of liquid. The actual peptide dose depends entirely on how much peptide mass you dissolved into that liquid volume.

Tesamorelin is supplied as lyophilised powder in 2mg or 5mg vials. Reconstitution converts solid peptide into injectable solution by adding sterile bacteriostatic water. The formula is:

Concentration (mg/mL) = Peptide mass (mg) ÷ Reconstitution volume (mL)

If you add 2mL bacteriostatic water to a 2mg vial, the resulting concentration is 1mg/mL (or 1000mcg/mL). To administer 500mcg, you draw 0.5mL (the 50-unit mark on a U-100 syringe). If you had added 1mL instead, the concentration would be 2mg/mL. And 0.5mL would deliver 1000mcg, double the intended dose. The syringe calibration doesn't change; the peptide concentration does. This article covers how to calculate dose volume from concentration, how to verify your math before the first injection, and what reconstitution volume to choose based on target dose frequency.

Step 1: Calculate Target Concentration Based on Prescribed Dose

Before opening the vial, determine the reconstitution volume that produces a concentration aligned with your protocol's dose increments. Research-grade tesamorelin protocols typically specify 500mcg to 2mg daily subcutaneous administration. If the prescribed dose is 1mg (1000mcg) and you're working with a 2mg vial, reconstituting with 2mL bacteriostatic water yields 1mg/mL. Meaning each 1mL draw delivers exactly one dose. This simplifies dosing but increases injection volume.

Alternatively, reconstituting the same 2mg vial with 1mL water produces 2mg/mL concentration. A 1mg dose now requires only 0.5mL (half the injection volume), but smaller dose adjustments become harder to measure accurately on standard insulin syringes. The trade-off: higher concentrations reduce injection volume but compress the margin for syringe measurement error; lower concentrations increase injection volume but make fractional dosing easier to visualise on syringe graduations.

For 500mcg daily protocols, reconstitute a 2mg vial with 4mL bacteriostatic water to achieve 0.5mg/mL (500mcg/mL). Each 1mL draw delivers one 500mcg dose. Four doses per vial. A 5mg vial reconstituted with 10mL yields the same 500mcg/mL concentration with ten doses per vial. The concentration formula remains constant: divide total peptide mass by total liquid volume. Write the calculated concentration directly on the vial label immediately after mixing. This prevents dosing errors across multi-day protocols where reconstitution date and concentration can otherwise be confused.

Step 2: Perform Sterile Reconstitution with Bacteriostatic Water

Tesamorelin reconstitution requires bacteriostatic water specifically. Not sterile water for injection, not saline. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative, allowing multi-dose vials to remain stable at 2–8°C for 28 days post-reconstitution. Sterile water lacks this preservative and supports bacterial growth within 24 hours once the vial seal is punctured. Using the wrong diluent is the single most common cause of peptide degradation in refrigerated storage.

Reconstitution steps: (1) Allow the lyophilised vial and bacteriostatic water vial to reach room temperature (15–20 minutes out of refrigeration). (2) Wipe both vial stoppers with alcohol prep pads and allow to air-dry for 30 seconds. (3) Draw the calculated volume of bacteriostatic water into a sterile syringe. (4) Insert the needle at a 45-degree angle into the peptide vial and inject the water slowly down the inside wall of the vial. Not directly onto the lyophilised powder. Direct injection onto the powder creates foam and denatures protein structure. (5) Withdraw the needle and gently swirl the vial in circular motions until the powder fully dissolves. Do not shake. Agitation introduces air bubbles that destabilise peptide bonds.

The solution should be clear and colourless once fully reconstituted. Cloudiness, particulates, or colour indicate contamination or denaturation. Discard the vial. Label the vial with reconstitution date, final concentration, and expiration date (28 days from mixing). Store at 2–8°C immediately. Never freeze reconstituted peptides. Ice crystal formation ruptures peptide structure irreversibly. Our team has found that the single most preventable reconstitution error is injecting air into the vial while drawing solution; the pressure differential pulls contaminants back through the needle on every subsequent draw, compromising sterility across the entire vial.

Step 3: Convert Microgram Dose to Syringe Volume Using Concentration

Once reconstituted, every dose calculation follows the same formula:

Dose volume (mL) = Desired dose (mcg) ÷ Concentration (mcg/mL)

If your protocol specifies 1mg (1000mcg) daily and you reconstituted a 5mg vial with 5mL bacteriostatic water, your concentration is 1mg/mL (1000mcg/mL). The dose volume is 1000mcg ÷ 1000mcg/mL = 1mL. On a U-100 insulin syringe, 1mL corresponds to the 100-unit mark. You draw to the top of the syringe barrel.

For fractional doses, the same formula applies. A 500mcg dose from a 2mg/mL solution requires 500mcg ÷ 2000mcg/mL = 0.25mL (25 units on a U-100 syringe). A 750mcg dose from a 1mg/mL solution requires 750mcg ÷ 1000mcg/mL = 0.75mL (75 units). Write the dose calculation on your protocol sheet before every administration. Mental math during syringe draw introduces error.

Insulin syringe calibrations: U-100 syringes display 100 units across 1mL, with major tick marks every 10 units (0.1mL) and minor tick marks every 2 units (0.02mL) on most brands. A 0.5mL draw sits exactly at the 50-unit midpoint. If your calculated dose volume falls between minor tick marks (e.g., 0.33mL = 33 units), round to the nearest visible graduation and accept ±2% dosing variance, or switch to a 0.5mL or 0.3mL syringe with finer graduations. Precision below 0.05mL (5 units) on standard U-100 syringes is unreliable. Adjust your reconstitution volume to avoid doses requiring this level of measurement.

Tesamorelin Reconstitution: Concentration vs. Dose Volume Comparison

What If: Tesamorelin Reconstitution Scenarios

What If I Accidentally Added the Wrong Volume of Bacteriostatic Water?

Recalculate the new concentration immediately using the actual volume added, then adjust future dose volumes accordingly. If you intended 2mL but added 3mL to a 2mg vial, your concentration is now 0.67mg/mL (667mcg/mL) instead of 1mg/mL. A 1mg dose requires 1.5mL instead of 1mL. The peptide remains viable, but every subsequent draw must account for the diluted concentration. Write the corrected concentration on the vial label and update your dosing protocol sheet to reflect the new dose volumes. The peptide is not wasted unless you exceed the maximum safe reconstitution volume (generally 5–10mL for a 2mg vial, beyond which concentration becomes too dilute for practical injection volumes).

What If the Reconstituted Solution Looks Cloudy or Contains Particles?

Discard the vial immediately. Cloudiness indicates either bacterial contamination or protein aggregation, both of which render the peptide unsafe and ineffective. Tesamorelin should reconstitute into a clear, colourless solution within 2–3 minutes of gentle swirling. Particulates suggest incomplete dissolution or contamination introduced during reconstitution (often from reusing needles or failing to sterilise vial stoppers). Do not attempt to filter or salvage the solution. Proper reconstitution technique. Sterile single-use needles, alcohol-prepped stoppers, and slow injection down the vial wall. Prevents this outcome in 99% of cases.

What If I Need to Dose Between Syringe Tick Marks?

Choose a reconstitution volume that aligns your target dose with visible syringe graduations, or accept ±2% dosing variance by rounding to the nearest mark. Standard U-100 insulin syringes have minor graduations every 2 units (0.02mL). If your calculated dose is 0.33mL (33 units). Which falls between the 32 and 34 marks. Drawing to 34 introduces approximately 3% overdose. For research protocols where this variance is unacceptable, reconstitute at a different concentration or switch to 0.5mL or 0.3mL syringes with finer 1-unit graduations. Precision below 0.05mL on standard syringes is unreliable regardless of technique.

The Unforgiving Truth About Peptide Concentration Math

Here's the honest answer: if you reconstitute a peptide without calculating the final concentration first, you are guessing at every dose. The syringe graduations don't change meaning based on what's inside the barrel. 50 units is always 0.5mL of liquid, whether that liquid contains 500mcg or 5000mcg of peptide. The only variable you control is concentration, and concentration is determined entirely by the reconstitution volume you choose. There is no margin for 'figuring it out as you go'. Peptide protocols operate in micrograms, and a 2× dosing error from incorrect dilution math can shift a compound from therapeutic range to side-effect threshold without any visible difference in injection volume. Measure twice, inject once.

Tesamorelin stability is unforgiving in one specific way most researchers underestimate: once reconstituted, the 28-day refrigerated shelf life is absolute. The benzyl alcohol preservative in bacteriostatic water suppresses bacterial growth, but it does not prevent peptide bond hydrolysis. Tesamorelin's growth-hormone-releasing mechanism degrades through oxidation and peptide fragmentation even under ideal 2–8°C storage. A vial stored for 35 days may still appear clear, but bioactivity drops measurably after day 28. Label expiration dates the moment you reconstitute, and discard on schedule regardless of remaining volume. Attempting to extend shelf life beyond the evidence-backed window is false economy.

Integrating Precision Tools into Research Peptide Protocols

Precision in peptide research extends beyond reconstitution math. Our experience working with laboratories across biologics research has shown that protocol reliability depends on three factors: exact peptide dosing, consistent handling procedures, and access to research-grade compounds with verified purity. At Real Peptides, every peptide batch undergoes exact amino-acid sequencing and third-party purity verification before release. Eliminating the concentration variance introduced by impure or incorrectly labeled compounds. When your protocol specifies 2mg tesamorelin, the vial contains 2mg ±2%. Not an approximation.

For research teams working across multiple peptide compounds, maintaining separate reconstitution calculators, sterile technique SOPs, and storage protocols for each molecule prevents cross-contamination of procedure. A misstep with BPC-157 reconstitution. Where concentration math differs due to smaller typical doses. Doesn't transfer to tesamorelin handling when each compound has its own documented workflow. You can explore the full range of research peptides with detailed handling guidance at our peptide collection. What separates reliable research outcomes from inconsistent results is not the complexity of the science. It's the rigor of the preparation.

If the calculated dose volume for your tesamorelin protocol doesn't align cleanly with syringe graduations, adjust the reconstitution volume before mixing. Not the dose after. A 2mg vial can be reconstituted with any volume from 1mL to 5mL and remain stable; the only constraint is ensuring your target dose translates to a measurable draw. Protocols demanding fractional-microgram precision require purpose-matched reconstitution planning upfront. Concentration math done correctly once eliminates dosing ambiguity across the entire 28-day vial lifespan.

faqs

[ { "question": "How do I calculate the dose volume if I reconstituted tesamorelin at a different concentration than standard protocols?", "answer": "Divide your target dose in micrograms by the actual concentration in mcg/mL. If you reconstituted a 5mg vial with 10mL (yielding 500mcg/mL) and need a 1mg (1000mcg) dose, the calculation is 1000mcg ÷ 500mcg/mL = 2mL. The formula works universally regardless of the reconstitution volume you chose. Concentration determines dose volume, and concentration is always peptide mass divided by liquid volume." }, { "question": "Can I use sterile water instead of bacteriostatic water to reconstitute tesamorelin?", "answer": "Only if you use the entire vial within 24 hours of reconstitution. Sterile water for injection lacks the 0.9% benzyl alcohol preservative that inhibits bacterial growth in multi-dose vials. Without preservative, any bacteria introduced during needle puncture can proliferate at refrigeration temperatures, contaminating the peptide solution. Bacteriostatic water extends safe multi-dose use to 28 days at 2–8°C. If your protocol requires more than one dose from a single vial, bacteriostatic water is non-negotiable." }, { "question": "What happens if I inject air into the tesamorelin vial while drawing the dose?", "answer": "Injecting air creates positive pressure inside the vial, which forces solution back through the needle when you withdraw. Potentially introducing airborne contaminants into the sterile environment. Over multiple draws, this pressure-driven backflow accumulates particulates and bacteria that compromise peptide stability. The correct technique: insert the needle, draw the dose volume, and withdraw immediately without injecting air. If the vial develops a vacuum over multiple draws, equalize pressure by inserting a separate sterile needle briefly to allow airflow, then remove it before the next draw." }, { "question": "How long does reconstituted tesamorelin remain stable at room temperature?", "answer": "Reconstituted tesamorelin degrades rapidly above 8°C. Room temperature (20–25°C) exposure for more than 2 hours measurably reduces bioactivity. Refrigerate the vial immediately after reconstitution and return it to 2–8°C storage within 5 minutes of each dose draw. If ambient temperature exposure exceeds 4 hours (e.g., during transport without a cooler), discard the vial. Peptide bond hydrolysis accelerates exponentially with temperature. What takes 28 days at 4°C can occur in 48 hours at 25°C." }, { "question": "Why does my tesamorelin dose volume seem larger than expected compared to other peptides?", "answer": "Dose volume is determined entirely by concentration, which varies by reconstitution choice. Tesamorelin protocols typically specify 500mcg to 2mg doses. Significantly higher mass than compounds like BPC-157 (200–500mcg) or thymosin beta-4 (750mcg). If you reconstitute a 5mg tesamorelin vial with 5mL bacteriostatic water (1mg/mL concentration), a 2mg dose requires 2mL injection volume. Four times the volume of a 500mcg dose from a 1mg/mL solution. Higher prescribed dose and lower concentration both increase injection volume; this is normal and does not indicate dilution error." }, { "question": "Can I reconstitute tesamorelin with saline instead of bacteriostatic water?", "answer": "Saline (0.9% sodium chloride) is isotonic but lacks bacteriostatic preservative, making it unsuitable for multi-dose vials. Reconstitution with saline requires single-dose use within 24 hours, the same limitation as sterile water. Additionally, some peptides exhibit reduced stability in saline compared to bacteriostatic water due to ionic interactions with chloride. Though tesamorelin tolerates saline reasonably well for immediate-use applications. For any protocol requiring refrigerated multi-dose storage, bacteriostatic water remains the evidence-backed standard." }, { "question": "What is the maximum reconstitution volume I can use without making the tesamorelin solution too dilute?", "answer": "Practical maximum is typically 10mL for a 5mg vial (0.5mg/mL concentration). Beyond this, dose volumes become impractically large for subcutaneous injection. A 2mg dose from a 0.5mg/mL solution requires 4mL injection volume, which exceeds the comfortable single-site subcutaneous injection limit (generally 1–1.5mL). Minimum concentration should keep individual dose volumes below 2mL to avoid split-site injections. For 2mg vials, reconstitute with no more than 4mL; for 5mg vials, no more than 10mL." }, { "question": "How do I verify my reconstitution math is correct before administering the first dose?", "answer": "Calculate the dose volume using the formula (desired dose in mcg ÷ concentration in mcg/mL), then reverse-check by multiplying dose volume by concentration. The result should equal your target dose. Example: if you want 1mg (1000mcg) from a 2mg/mL solution, dose volume is 1000 ÷ 2000 = 0.5mL. Reverse check: 0.5mL × 2000mcg/mL = 1000mcg. Write both calculations on your protocol sheet and have a second researcher verify before the first draw. Dose calculation errors are caught at this stage. Not after injection." }, { "question": "Does tesamorelin concentration affect injection site reactions or efficacy?", "answer": "Higher concentrations (above 2mg/mL) can increase localized injection site discomfort due to higher peptide density in a smaller injection volume, but they do not alter systemic bioavailability or efficacy. Subcutaneous absorption depends on total peptide mass administered, not the concentration or volume injected. A 1mg dose delivers identical systemic exposure whether injected as 0.5mL of 2mg/mL solution or 1mL of 1mg/mL solution. Choose reconstitution volume based on dosing convenience and injection comfort, not perceived efficacy differences." }, { "question": "What should I do if I accidentally drew more tesamorelin than my calculated dose volume?", "answer": "Do not inject the excess. Expel it back into the vial or into a sterile waste container, then redraw the correct volume. Administering an overdose, even a small one, introduces unnecessary variance into your protocol and may trigger dose-dependent side effects. If you've already removed the needle from the vial, do not re-insert it to return excess solution. This risks contaminating the vial. Dispose of the excess, draw a fresh dose with a new sterile needle, and verify the volume before injection. Precision matters more than conserving a few extra microliters." } ] }

References

Peer-reviewed sources on Tesamorelin indexed in PubMed, listed for research context. Real Peptides supplies Tesamorelin for laboratory research use only.

1. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obesity research & clinical practice, 2026. PMID 41545261. doi:10.1016/j.orcp.2026.01.002
2. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs, 2011. PMID 21668043. doi:10.2165/11202240-000000000-00000
3. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. The Journal of infectious diseases, 2025. PMID 39813152. doi:10.1093/infdis/jiaf012
4. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS (London, England), 2024. PMID 38905488. doi:10.1097/QAD.0000000000003965
5. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial. Journal of clinical and translational science, 2023. PMID 36845310. doi:10.1017/cts.2022.515
6. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS (London, England), 2021. PMID 33756511. doi:10.1097/QAD.0000000000002897
7. Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific reports, 2021. PMID 34006921. doi:10.1038/s41598-021-89966-y
8. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI insight, 2020. PMID 32701508. doi:10.1172/jci.insight.140134